Stay updated on ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Added Revision: v3.5.0; Removed Revision: v3.4.3 in the record history.
    Difference
    0.1%
    Check dated 2026-03-21T09:09:47.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Revision history updated to add entry v3.4.3 and remove v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-06T20:36:02.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The page now shows that Revision: v3.4.2 was added and Revision: v3.4.1 was removed, as part of revision history updates. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:22:08.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    New history entry v3.4.1 added and v3.4.0 removed, updating the record history. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-05T22:18:10.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The history shows a new revision entry (v3.3.4) added to the page and the prior revision (v3.3.3) superseded. This appears to be a routine record-keeping update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T04:41:57.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The record history shows minor site updates: a new Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-24T21:36:12.000Z thumbnail image

Stay in the know with updates to ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ALKS 4230 and Pembrolizumab in Head and Neck Cancer Clinical Trial page.